Review
Copyright ©The Author(s) 2021.
World J Clin Oncol. May 24, 2021; 12(5): 290-308
Published online May 24, 2021. doi: 10.5306/wjco.v12.i5.290
Table 1 Ongoing clinical trials investigating chimeric antigen receptor-T cell therapy in the treatment of hepatocellular carcinoma according to ClinicalTrials.gov
Product
Phase
Estimated completion
Study/identifier
GPC3- CAR-TINovember 2021NCT04121273
CD147- CAR-TIMay 2022NCT03993743
GPC3- CAR-TIJune 2022NCT03980288
CAR-CLD18N/ADecember 2023NCT03302403
GPC3- CAR-TIMay 2024NCT03884751
GPC3/TGF-CAR-TIAugust 2024NCT03198546
GPC3- CAR-TIOctober 2036NCT02905188
CAR: Chimeric antigen receptor; CD: Cluster of differentiation; GPC3: Glypican-3; TGF: Transforming growth factor.
Table 2 Ongoing clinical trials investigating T cell receptor engineered T cells in the treatment of hepatocellular carcinoma according to ClinicalTrials.gov
Product/target
Phase
Estimated completion
Study/identifier
C-TCR055/AFPIApril 2021NCT03971747
C-TCR055/AFPINovember 2021NCT04368182
HBV-TCR T cell/HBV AgIJune 2024NCT03899415
IMA202-101/MAGE A1IJune 2024NCT03441100
AFP T cells/AFPIJune 2026NCT03132792
AFP: Alpha fetoprotein; HBV: Hepatitis B virus; Ag: Antigen; MAGE: Melanoma antigen gene protein.
Table 3 Ongoing clinical trials investigating cancer vaccines and oncolytic viruses in the treatment of hepatocellular carcinoma according to ClinicalTrials.gov
Product
Phase
Estimated completion
Study/identifier
OV telomelysin (OBP-301)IApril 2021NCT02293850
DC vaccineIIApril 2022NCT04317248
DC vaccine + pneumococcal 13IMay 2022NCT03942328
OV M1-c6v1IOctober 2022NCT04665362
DC vaccineIJune 2023NCT04147078
DSP-7888 PV + nivolumab or pembrolizumabI/IIFebruary 2024NCT03311334
DNAJB1-PRKACA fusion kinase vaccineIMarch 2024NCT04248569
TAEK-VAC-HerBy vaccineI/IIDecember 2024NCT04246671
DC: Dendritic cell; OV: Oncolytic virus; PV: Peptide vaccine.